[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 58-year-old man with hypertrophic cardiomyopathy (HCM), MYH7 mutation, recurrent syncope, asymmetric septal hypertrophy, resting LVOT gradient 80 mmHg, symptoms persistent despite optimal beta-blocker therapy. These indicate symptomatic obstructive HCM refractory to first-line therapy, warranting escalation of medical management before invasive options. Main logical issue(s), if any: None; stem provides sufficient details for discriminating a single best next step without contradictions or underspecification, as options allow clear hierarchy based on guideline progression. Main medical accuracy issue(s), if any: None; aligns with 2020 AHA/ACC HCM guidelines, where adding disopyramide (Class 2a) to beta-blockers is appropriate for persistent symptoms in obstructive HCM prior to septal reduction therapies (alcohol ablation or myectomy, Class 1 for severe refractory cases). Pacemaker is Class 2b/3 for select cases, and CRT is not indicated without systolic dysfunction or dyssynchrony. The item's logic correctly prioritizes stepwise management without inaccuracies or outdated elements. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 58-year-old man with hypertrophic cardiomyopathy (HCM), MYH7 mutation, recurrent syncope, asymmetric septal hypertrophy, resting LVOT gradient 80 mmHg, symptoms persistent despite optimal beta-blocker therapy. These indicate symptomatic obstructive HCM refractory to first-line therapy, warranting escalation of medical management before invasive options. Main logical issue(s), if any: None; stem provides sufficient details for discriminating a single best next step without contradictions or underspecification, as options allow clear hierarchy based on guideline progression. Main medical accuracy issue(s), if any: None; aligns with 2020 AHA/ACC HCM guidelines, where adding disopyramide (Class 2a) to beta-blockers is appropriate for persistent symptoms in obstructive HCM prior to septal reduction therapies (alcohol ablation or myectomy, Class 1 for severe refractory cases). Pacemaker is Class 2b/3 for select cases, and CRT is not indicated without systolic dysfunction or dyssynchrony. The item's logic correctly prioritizes stepwise management without inaccuracies or outdated elements. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the syndrome associated with PAX2 mutation in a child with recurrent UTIs, VUR, and mild hydronephrosis. Key discriminating findings: recurrent UTIs despite prophylaxis, VUR on VCUG, mild hydronephrosis on ultrasound, and PAX2 gene mutation (positive clue driving diagnosis); no mention of eye, ear, or genital anomalies (negative clues excluding alternatives). Most likely diagnosis: Renal coloboma syndrome, linked to PAX2 mutations causing renal anomalies like VUR and hypoplasia. Keyed answer B fits perfectly as PAX2 is pathognomonic for renal coloboma syndrome; no assumptions needed. Alternatives: A (Denys-Drash) incorrect due to WT1 mutation, lacks VUR focus; C (Branchio-oto-renal) linked to EYA1, features branchial/ear issues absent here; D (Alport) involves collagen IV, typically hematuria/nephritis not highlighted; E (Frasier) also WT1, with pseudohermaphroditism not mentioned. Logical validity: V, stem supports unique best answer B without contradictions or underspecification. Medical accuracy: Consistent with mainstream genetics; PAX2 mutations definitively cause renal coloboma syndrome per current standards (e.g., OMIM, pediatric nephrology guidelines). No inaccuracies or outdated info. Minimal fix: None required; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the syndrome associated with PAX2 mutation in a child with recurrent UTIs, VUR, and mild hydronephrosis. Key discriminating findings: recurrent UTIs despite prophylaxis, VUR on VCUG, mild hydronephrosis on ultrasound, and PAX2 gene mutation (positive clue driving diagnosis); no mention of eye, ear, or genital anomalies (negative clues excluding alternatives). Most likely diagnosis: Renal coloboma syndrome, linked to PAX2 mutations causing renal anomalies like VUR and hypoplasia. Keyed answer B fits perfectly as PAX2 is pathognomonic for renal coloboma syndrome; no assumptions needed. Alternatives: A (Denys-Drash) incorrect due to WT1 mutation, lacks VUR focus; C (Branchio-oto-renal) linked to EYA1, features branchial/ear issues absent here; D (Alport) involves collagen IV, typically hematuria/nephritis not highlighted; E (Frasier) also WT1, with pseudohermaphroditism not mentioned. Logical validity: V, stem supports unique best answer B without contradictions or underspecification. Medical accuracy: Consistent with mainstream genetics; PAX2 mutations definitively cause renal coloboma syndrome per current standards (e.g., OMIM, pediatric nephrology guidelines). No inaccuracies or outdated info. Minimal fix: None required; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute segmental pulmonary embolism post-long-haul flight, oral contraceptive use, positive family history for thrombophilia, and elevated factor VIII levels, with no mention of hemodynamic instability, pregnancy, severe renal impairment, or active cancer. These support initial anticoagulation without need for bridging or thrombolysis. The question asks for the most appropriate initial anticoagulant, and B (direct oral anticoagulant like rivaroxaban) aligns with current guidelines (e.g., ACCP/ASH) preferring DOACs for uncomplicated PE due to convenience and efficacy. Main logical issue(s): none; the stem provides sufficient details to discriminate options without contradictions or underspecification, allowing a unique best answer. Alternatives are inferior: A is valid but less convenient requiring monitoring; C adds unnecessary thrombolysis absent instability; D is not standard monotherapy for PE; E is inappropriate for venous thromboembolism. Main medical accuracy issue(s): none; the item reflects modern standards favoring DOACs over vitamin K antagonists for most non-high-risk VTE cases, with accurate rationale on alternatives. Minimal fix: none needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute segmental pulmonary embolism post-long-haul flight, oral contraceptive use, positive family history for thrombophilia, and elevated factor VIII levels, with no mention of hemodynamic instability, pregnancy, severe renal impairment, or active cancer. These support initial anticoagulation without need for bridging or thrombolysis. The question asks for the most appropriate initial anticoagulant, and B (direct oral anticoagulant like rivaroxaban) aligns with current guidelines (e.g., ACCP/ASH) preferring DOACs for uncomplicated PE due to convenience and efficacy. Main logical issue(s): none; the stem provides sufficient details to discriminate options without contradictions or underspecification, allowing a unique best answer. Alternatives are inferior: A is valid but less convenient requiring monitoring; C adds unnecessary thrombolysis absent instability; D is not standard monotherapy for PE; E is inappropriate for venous thromboembolism. Main medical accuracy issue(s): none; the item reflects modern standards favoring DOACs over vitamin K antagonists for most non-high-risk VTE cases, with accurate rationale on alternatives. Minimal fix: none needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Behçet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Symmetric polyarthritis, morning stiffness >1 hour, trunk rash, positive ACPA, elevated inflammatory markers, progression despite methotrexate, and crucially, NLRP3 gene mutation revealed by genetic testing. These point to an autoinflammatory condition mimicking rheumatoid arthritis (RA) but distinguished by the specific mutation. The NLRP3 mutation is pathognomonic for cryopyrin-associated periodic syndrome (CAPS), making B the unique best fit; CAPS can present with arthritis, urticarial rash, and poor response to DMARDs like methotrexate. Alternatives are inferior: A (RA) fits clinical and ACPA but lacks NLRP3 mutation; C (AOSD) may have rash and arthritis but no NLRP3 association; D (Behçet's) typically involves oral/genital ulcers, not symmetric polyarthritis or NLRP3; E (SLE) features autoantibodies like ANA, not NLRP3. No main logical issues; the item allows discrimination via the mutation as the decisive clue, with no contradictions or underspecification preventing a single best choice. Main medical accuracy issue: CAPS is an autoinflammatory disorder typically seronegative; positive ACPA is highly specific for RA and clinically unrealistic in CAPS, potentially misleading learners on diagnostic specificity. Minimal fix: Revise stem to 'negative anti-citrullinated protein antibodies' to align with standard CAPS presentation and eliminate atypical autoantibody positivity.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Symmetric polyarthritis, morning stiffness >1 hour, trunk rash, positive ACPA, elevated inflammatory markers, progression despite methotrexate, and crucially, NLRP3 gene mutation revealed by genetic testing. These point to an autoinflammatory condition mimicking rheumatoid arthritis (RA) but distinguished by the specific mutation. The NLRP3 mutation is pathognomonic for cryopyrin-associated periodic syndrome (CAPS), making B the unique best fit; CAPS can present with arthritis, urticarial rash, and poor response to DMARDs like methotrexate. Alternatives are inferior: A (RA) fits clinical and ACPA but lacks NLRP3 mutation; C (AOSD) may have rash and arthritis but no NLRP3 association; D (Behçet's) typically involves oral/genital ulcers, not symmetric polyarthritis or NLRP3; E (SLE) features autoantibodies like ANA, not NLRP3. No main logical issues; the item allows discrimination via the mutation as the decisive clue, with no contradictions or underspecification preventing a single best choice. Main medical accuracy issue: CAPS is an autoinflammatory disorder typically seronegative; positive ACPA is highly specific for RA and clinically unrealistic in CAPS, potentially misleading learners on diagnostic specificity. Minimal fix: Revise stem to 'negative anti-citrullinated protein antibodies' to align with standard CAPS presentation and eliminate atypical autoantibody positivity.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (secondary N). Verdict on keyed answer: Not uniquely determinable / No defensible answer. Key stem clues include type 1 diabetes mellitus (implying baseline low beta-cell function), recurrent hypoglycemia despite insulin adjustments, nocturnal pattern, elevated proinsulin, and low C-peptide. These fail to drive a unique best answer because elevated proinsulin suggests ongoing beta-cell activity (proinsulin production), while low C-peptide indicates suppressed or absent endogenous insulin secretion, creating an incompatible lab profile without explanation. Main logical issue: Internal contradiction in laboratory findings (elevated proinsulin contradicting low C-peptide) renders the item incoherent and unsolvable, as no option aligns perfectly with both results—e.g., B requires low proinsulin, A requires high C-peptide. This leads to no defensible answer among choices. Main medical accuracy issues: The rationale incorrectly states elevated proinsulin occurs in factitious hypoglycemia from exogenous insulin due to suppression, but standard knowledge indicates suppression lowers proinsulin; the keyed answer (B) mismatches typical labs (low proinsulin expected). Item misrepresents pathophysiology, potentially misleading on hypoglycemia evaluation. Minimal fix: Edit stem to change 'elevated proinsulin levels' to 'elevated insulin levels' to align with factitious hypoglycemia (low C-peptide, high insulin, low proinsulin), making B uniquely defensible and accurate.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (secondary N). Verdict on keyed answer: Not uniquely determinable / No defensible answer. Key stem clues include type 1 diabetes mellitus (implying baseline low beta-cell function), recurrent hypoglycemia despite insulin adjustments, nocturnal pattern, elevated proinsulin, and low C-peptide. These fail to drive a unique best answer because elevated proinsulin suggests ongoing beta-cell activity (proinsulin production), while low C-peptide indicates suppressed or absent endogenous insulin secretion, creating an incompatible lab profile without explanation. Main logical issue: Internal contradiction in laboratory findings (elevated proinsulin contradicting low C-peptide) renders the item incoherent and unsolvable, as no option aligns perfectly with both results—e.g., B requires low proinsulin, A requires high C-peptide. This leads to no defensible answer among choices. Main medical accuracy issues: The rationale incorrectly states elevated proinsulin occurs in factitious hypoglycemia from exogenous insulin due to suppression, but standard knowledge indicates suppression lowers proinsulin; the keyed answer (B) mismatches typical labs (low proinsulin expected). Item misrepresents pathophysiology, potentially misleading on hypoglycemia evaluation. Minimal fix: Edit stem to change 'elevated proinsulin levels' to 'elevated insulin levels' to align with factitious hypoglycemia (low C-peptide, high insulin, low proinsulin), making B uniquely defensible and accurate.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include ischemic cardiomyopathy with EF 25%, sustained VT from reentrant circuit in infarct border zone, hemodynamic stability, and recurrence despite amiodarone, pointing to need for substrate-targeted intervention. The clinical problem asks for the most appropriate next step in managing refractory scar-related VT. Discriminating findings: positive clues are identified reentrant mechanism and drug refractoriness; negative clues include stability precluding emergent measures. Most likely next step is ablation to eliminate the circuit. Keyed answer A (catheter ablation) fits as it directly addresses the arrhythmia substrate per guidelines. Alternatives: B (ICD upgrade) targets HF symptoms but not VT circuits; C (mexiletine) is adjunctive but less effective for scar VT; D (stellate ganglionectomy) and E (cardiac sympathetic denervation) are invasive options for highly refractory cases, not first-line after failed amiodarone. No main logical issues; stem allows clear discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with AHA/ACC guidelines for VT ablation in structural heart disease refractory to antiarrhythmics, reflecting current standards without outdated elements. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include ischemic cardiomyopathy with EF 25%, sustained VT from reentrant circuit in infarct border zone, hemodynamic stability, and recurrence despite amiodarone, pointing to need for substrate-targeted intervention. The clinical problem asks for the most appropriate next step in managing refractory scar-related VT. Discriminating findings: positive clues are identified reentrant mechanism and drug refractoriness; negative clues include stability precluding emergent measures. Most likely next step is ablation to eliminate the circuit. Keyed answer A (catheter ablation) fits as it directly addresses the arrhythmia substrate per guidelines. Alternatives: B (ICD upgrade) targets HF symptoms but not VT circuits; C (mexiletine) is adjunctive but less effective for scar VT; D (stellate ganglionectomy) and E (cardiac sympathetic denervation) are invasive options for highly refractory cases, not first-line after failed amiodarone. No main logical issues; stem allows clear discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with AHA/ACC guidelines for VT ablation in structural heart disease refractory to antiarrhythmics, reflecting current standards without outdated elements. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (contradiction; secondary U). Verdict on keyed answer: Not uniquely determinable due to internal inconsistency; keyed B is medically indefensible. Key stem clues: 8-year-old girl with short stature, failure to thrive, delayed bone age, low IGF-1, normal GH stimulation, and IGF1R gene mutation. These drive toward primary IGF-1 deficiency (low IGF-1, normal GH), where IGF-1 replacement (B) would be best, but IGF1R mutation implies IGF-1 resistance typically with normal/elevated IGF-1, contradicting the low IGF-1 finding and making GH or IGF-1 therapies ineffective. Main logical issue(s): Contradiction between low IGF-1 lab result and IGF1R mutation, which classically features elevated IGF-1 due to compensatory feedback, rendering the vignette incoherent and underspecified for a unique diagnosis/management without assuming unstated details. Main medical accuracy issue(s): Inaccurate pathophysiology—IGF1R mutations cause resistance, not primary deficiency with low IGF-1; IGF-1 replacement is not indicated for receptor defects (ineffective) and contradicts guidelines (e.g., rhIGF-1 approved for primary IGF-1 deficiency like IGF1 mutations, not IGF1R). Item misleads on endocrine growth disorders. Minimal fix: Revise genetic testing to 'IGF1 gene mutation' to align with low IGF-1 and support keyed B as unique best answer.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (contradiction; secondary U). Verdict on keyed answer: Not uniquely determinable due to internal inconsistency; keyed B is medically indefensible. Key stem clues: 8-year-old girl with short stature, failure to thrive, delayed bone age, low IGF-1, normal GH stimulation, and IGF1R gene mutation. These drive toward primary IGF-1 deficiency (low IGF-1, normal GH), where IGF-1 replacement (B) would be best, but IGF1R mutation implies IGF-1 resistance typically with normal/elevated IGF-1, contradicting the low IGF-1 finding and making GH or IGF-1 therapies ineffective. Main logical issue(s): Contradiction between low IGF-1 lab result and IGF1R mutation, which classically features elevated IGF-1 due to compensatory feedback, rendering the vignette incoherent and underspecified for a unique diagnosis/management without assuming unstated details. Main medical accuracy issue(s): Inaccurate pathophysiology—IGF1R mutations cause resistance, not primary deficiency with low IGF-1; IGF-1 replacement is not indicated for receptor defects (ineffective) and contradicts guidelines (e.g., rhIGF-1 approved for primary IGF-1 deficiency like IGF1 mutations, not IGF1R). Item misleads on endocrine growth disorders. Minimal fix: Revise genetic testing to 'IGF1 gene mutation' to align with low IGF-1 and support keyed B as unique best answer.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe abdominal pain, vomiting, CT-confirmed acute pancreatitis with necrosis, hypotension, acute kidney injury, and serum triglycerides of 1200 mg/dL, pointing to hypertriglyceridemic pancreatitis requiring acute triglyceride-lowering intervention. The question asks for the most appropriate initial management for hypertriglyceridemia in this context. Insulin infusion (B) is defensible as best due to its rapid enhancement of lipoprotein lipase activity, effectively reducing triglycerides in acute settings, especially with complications like necrosis and organ failure. Alternatives are inferior: Plasmapheresis (A) is typically reserved for refractory cases with triglycerides >1000 mg/dL not responding to initial therapy; Fibrates (C), Niacin (D), and Statins (E) are oral agents suited for long-term outpatient management, not acute inpatient care. No main logical issues, as the stem provides sufficient details for discriminating a unique best answer without contradictions or underspecification. No main medical accuracy issues; this aligns with current guidelines (e.g., American College of Gastroenterology) recommending insulin infusion for acute hypertriglyceridemic pancreatitis, with plasmapheresis as second-line. Minimal fix: N/A, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe abdominal pain, vomiting, CT-confirmed acute pancreatitis with necrosis, hypotension, acute kidney injury, and serum triglycerides of 1200 mg/dL, pointing to hypertriglyceridemic pancreatitis requiring acute triglyceride-lowering intervention. The question asks for the most appropriate initial management for hypertriglyceridemia in this context. Insulin infusion (B) is defensible as best due to its rapid enhancement of lipoprotein lipase activity, effectively reducing triglycerides in acute settings, especially with complications like necrosis and organ failure. Alternatives are inferior: Plasmapheresis (A) is typically reserved for refractory cases with triglycerides >1000 mg/dL not responding to initial therapy; Fibrates (C), Niacin (D), and Statins (E) are oral agents suited for long-term outpatient management, not acute inpatient care. No main logical issues, as the stem provides sufficient details for discriminating a unique best answer without contradictions or underspecification. No main medical accuracy issues; this aligns with current guidelines (e.g., American College of Gastroenterology) recommending insulin infusion for acute hypertriglyceridemic pancreatitis, with plasmapheresis as second-line. Minimal fix: N/A, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 35-year-old with seropositive RA on infliximab presenting with fever, weight loss, lymphadenopathy; biopsy revealing non-caseating granulomas; elevated serum ACE. These clues point to infliximab-induced sarcoidosis as the most likely diagnosis, a known rare complication of TNF inhibitors mimicking sarcoidosis without caseation. Main logical issue(s): None; the stem provides sufficient discriminating details (non-caseating granulomas distinguish from TB; drug context favors B over primary sarcoidosis or other granulomatous diseases). Main medical accuracy issue(s): None; aligns with current rheumatology knowledge on TNF inhibitor side effects, including granulomatous reactions with elevated ACE, per major guidelines and case reports. The item's logic correctly associates non-caseating granulomas with sarcoid-like reactions rather than caseating ones in TB. Minimal fix: None required, as the item is unambiguous and accurate; optionally, add 'primary sarcoidosis' as a distractor to enhance discrimination, but not necessary.\\n\\nBest-answer defensibility: a) The question asks for the most likely diagnosis in an RA patient on infliximab with systemic symptoms and non-caseating granulomatous lymphadenopathy. b) Key findings: infliximab use (positive clue for drug-induced reaction), non-caseating granulomas (negative for infection like TB), elevated ACE (supports sarcoid-like process). c) Implied diagnosis: Infliximab-induced sarcoidosis. d) Keyed answer B fits perfectly as a recognized adverse effect matching all features; assumes standard knowledge of TNF inhibitor risks. e) A: Worse due to typical caseation in TB; C: Lymphoma lacks granulomas; D: Fungal infections often caseating or culture-positive; E: Amyloidosis not granulomatous.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 35-year-old with seropositive RA on infliximab presenting with fever, weight loss, lymphadenopathy; biopsy revealing non-caseating granulomas; elevated serum ACE. These clues point to infliximab-induced sarcoidosis as the most likely diagnosis, a known rare complication of TNF inhibitors mimicking sarcoidosis without caseation. Main logical issue(s): None; the stem provides sufficient discriminating details (non-caseating granulomas distinguish from TB; drug context favors B over primary sarcoidosis or other granulomatous diseases). Main medical accuracy issue(s): None; aligns with current rheumatology knowledge on TNF inhibitor side effects, including granulomatous reactions with elevated ACE, per major guidelines and case reports. The item's logic correctly associates non-caseating granulomas with sarcoid-like reactions rather than caseating ones in TB. Minimal fix: None required, as the item is unambiguous and accurate; optionally, add 'primary sarcoidosis' as a distractor to enhance discrimination, but not necessary.\n\nBest-answer defensibility: a) The question asks for the most likely diagnosis in an RA patient on infliximab with systemic symptoms and non-caseating granulomatous lymphadenopathy. b) Key findings: infliximab use (positive clue for drug-induced reaction), non-caseating granulomas (negative for infection like TB), elevated ACE (supports sarcoid-like process). c) Implied diagnosis: Infliximab-induced sarcoidosis. d) Keyed answer B fits perfectly as a recognized adverse effect matching all features; assumes standard knowledge of TNF inhibitor risks. e) A: Worse due to typical caseation in TB; C: Lymphoma lacks granulomas; D: Fungal infections often caseating or culture-positive; E: Amyloidosis not granulomatous.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K\\nVerdict on keyed answer: Miskeyed\\n\\nThe clinical problem is identifying the most appropriate pharmacologic therapy for a 42-year-old woman with acromegaly and persistently elevated IGF-1 after transsphenoidal surgery, who declines further surgery.\\nKey discriminating findings: Acromegaly diagnosis, unsuccessful surgery with elevated IGF-1, no mention of prior medical therapy or adenoma characteristics (e.g., prolactin co-secretion).\\nMost likely next step: Initiate first-line medical therapy with a somatostatin receptor ligand (SRL) like octreotide, per Endocrine Society guidelines.\\nEvaluation of keyed answer (B. Pegvisomant): It's a GH receptor antagonist effective for SRL-resistant cases, but the stem lacks evidence of SRL failure, requiring an unstated assumption.\\nAlternative choices: A. Cabergoline - dopamine agonist, less potent for pure GH adenomas without prolactin elevation. C. Octreotide - standard first-line SRL post-surgery. D. Pasireotide - second-line SRL for octreotide-resistant cases. E. Bromocriptine - similar to A, outdated for primary use.\\nMain logical issue: A unique best answer (C. Octreotide) exists based on stem, but the key (B) mismatches it, fitting the miskeyed definition.\\nMain medical accuracy issue: The implied logic skips SRLs and jumps to pegvisomant, contradicting guidelines that recommend SRLs as initial pharmacologic therapy post-surgery.\\nMinimal fix: Add 'despite octreotide therapy' to the stem to justify pegvisomant as best.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K\nVerdict on keyed answer: Miskeyed\n\nThe clinical problem is identifying the most appropriate pharmacologic therapy for a 42-year-old woman with acromegaly and persistently elevated IGF-1 after transsphenoidal surgery, who declines further surgery.\nKey discriminating findings: Acromegaly diagnosis, unsuccessful surgery with elevated IGF-1, no mention of prior medical therapy or adenoma characteristics (e.g., prolactin co-secretion).\nMost likely next step: Initiate first-line medical therapy with a somatostatin receptor ligand (SRL) like octreotide, per Endocrine Society guidelines.\nEvaluation of keyed answer (B. Pegvisomant): It's a GH receptor antagonist effective for SRL-resistant cases, but the stem lacks evidence of SRL failure, requiring an unstated assumption.\nAlternative choices: A. Cabergoline - dopamine agonist, less potent for pure GH adenomas without prolactin elevation. C. Octreotide - standard first-line SRL post-surgery. D. Pasireotide - second-line SRL for octreotide-resistant cases. E. Bromocriptine - similar to A, outdated for primary use.\nMain logical issue: A unique best answer (C. Octreotide) exists based on stem, but the key (B) mismatches it, fitting the miskeyed definition.\nMain medical accuracy issue: The implied logic skips SRLs and jumps to pegvisomant, contradicting guidelines that recommend SRLs as initial pharmacologic therapy post-surgery.\nMinimal fix: Add 'despite octreotide therapy' to the stem to justify pegvisomant as best.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}]